AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01135459
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to CEP-33457 will be administered per schedule specified in the arm description.
Trial: NCT02485509
Drug: VM-1500/Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VM-1500 or Placebo
Trial: NCT04073511
Drug: Samsoeum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This drug is a commercially available drug, manufactured according to MFDS regulations and the Preparation of granules, General rule of formulation, Korean Pharmacopoeia. 3.37g of a packet, 3 times a day, the total daily dose is 10.11g. Total duration of administration is up to 8 days.
Trial: NCT04073511
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: It is composed of lactose carb, corn starch, caramel pigment, and ginseng flavor powder. It is brown granule and made to be recognized as Korean medicine. Take a total of 9.0g, 3.0g each, three times a day. The total duration of administration is up to 8 days.
Trial: NCT01771991
Drug: Topical Sodermix Dismutase in the form of Sodermix (SOD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
Trial: NCT01771991
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
Trial: NCT00272831
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 tablet twice daily
Trial: NCT01794507
Drug: ABT-199
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
Trial: NCT00288574
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00288574
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02078219
Drug: RDEA3170
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT02078219
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Treatment
Trial: NCT02317601
Drug: placebo saline
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT05290506
Drug: Dipeptidyl-Peptidase IV Inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All subjects were given linagliptin 5mg once daily for 12 weeks. Comparison of their OGTT response at week 0 and week 12
Trial: NCT04474197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matched to VX-864 for oral administration.
Trial: NCT02289196
Drug: Vx-006: 0,5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289196
Drug: Vx-006: 1mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289196
Drug: Vx-006: 5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02289196
Drug: Vx-006: 10mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04279119
Drug: ARQ-151- cream 0.3%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARQ-151 cream 0.3% applied to chronic plaque psoriasis lesions once a day for 2 weeks
Trial: NCT02051751
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
Trial: NCT00392834
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given IV
Trial: NCT00392834
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given IV
Trial: NCT00392834
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given IV
Trial: NCT00392834
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: given intrathecally
Trial: NCT00392834
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: given intrathecally
Trial: NCT03999099
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00659386
Drug: Intravenous immunoglobulin therapy
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
Trial: NCT03394651
Drug: Oral medications to treat lower urinary tract symptoms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in this group will receive oral medication(s) depending on doctors' prescriptions.
Trial: NCT00190229
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide
Trial: NCT00412958
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal injection of placebo
Trial: NCT02620423
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
Trial: NCT02620423
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
Trial: NCT02188121
Drug: Simvastatin
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 3-hydroxy-3-methylglutaryl-coenzyme (HMG-CoA) reductase inhibitors
Trial: NCT03748706
Drug: PTI-125, 100 mg tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PTI-125, 100 mg tablets taken twice a day for 28 days
Trial: NCT03610516
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple doses of placebo intravenous infusion
Trial: NCT02994732
Drug: [14C]-BVD-523
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-BVD-523 administered as a 600-mg (approximately 200 µCi) oral dose to 6 healthy male subjects following a 2-hour fast from food (not including water) that follows breakfast.
Trial: NCT00952861
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg QD in 5 days
Trial: NCT00952861
Drug: Placebo (matching)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo QD i 5 days
Trial: NCT00164008
Drug: zoledronic acid vs pamidronate
RxNorm normalized name: Pamidronic acid
DrugBank: Pamidronic acid (DB00282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01938911
Drug: Syntocinon-Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal oxytocin (24 IU)
Trial: NCT01288170
Drug: Nebcinal Tobi
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01288170
Drug: Tobi Nebcinal
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02412189
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine therapy to maintain preanesthesia blood pressure
Trial: NCT00402324
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, capsules, by mouth every evening, daily, for 6 weeks.
Trial: NCT04023383
Drug: 40 cc HyaRegen NCH gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an extensive bleeding control the patients in the intervention group had 40 mL of HyaRegen NCH gel instilled into the peritoneal cavity.
Trial: NCT04023383
Drug: 40 cc sterile saline solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After an extensive bleeding control the patients in the control group had 40 cc sterile saline solution compatible with the body temperature.
Trial: NCT01938911
Drug: Placebo of syntocinon
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal administration
Trial: NCT00191399
Drug: Fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00122616
Drug: HIV antiretroviral therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
Trial: NCT00637624
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo once every 3 weeks intravenous saline fluid
Trial: NCT02466425
Drug: SHP465
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12.5mg and 25mg capsules (one capsule daily)
Trial: NCT02466425
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsule that appear identical in size, weight, shape, color
Trial: NCT02808325
Drug: Gelaspan 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelaspan 4% combined with Sterofundin ISO
Trial: NCT02808325
Drug: Gelofusine 4%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gelofusine 4% combined with Sodium Chloride
Trial: NCT01072136
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
Trial: NCT00112658
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00112658
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02534012
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
Trial: NCT03107858
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Trial: NCT03107858
Drug: Dopamine
RxNorm normalized name: Dopamine
DrugBank: Dopamine (DB00988)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
Trial: NCT01111734
Drug: fMRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
Trial: NCT03035864
Drug: rhNGF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Drop 20 μg/mL
Trial: NCT03098433
Drug: Liothyronine
RxNorm normalized name: Liothyronine
DrugBank: Liothyronine (DB00279)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose
Trial: NCT03098433
Drug: Levothyroxine
RxNorm normalized name: Levothyroxine
DrugBank: Levothyroxine (DB00451)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Active comparator
Trial: NCT03098433
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT00460031
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20mg qam 10mg qhs
Trial: NCT02564614
Drug: RO7070179
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
Trial: NCT01802593
Drug: AZATHIOPRINE or METHOTREXATE
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
Trial: NCT01802593
Drug: AZATHIOPRINE or METHOTREXATE
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)~Thiopurine therapy 2 weeks
Trial: NCT00804050
Drug: infusion A: rEPO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
Trial: NCT02505022
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
Trial: NCT01637532
Drug: Carboplatin and Caelyx or doxorubicin
RxNorm normalized name: doxorubicin Injection [Caelyx]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
Trial: NCT02493361
Drug: pIL-12
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04185077
Drug: Heparin
RxNorm normalized name: Heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: a bolus dose of 100 U/kg was administered according to current guidelines.Additional heparinwasadministered if the post-bolus activated clotting time was less than 225 seconds.
Trial: NCT00752921
Drug: etoricoxib
RxNorm normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg
Trial: NCT00752921
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT04090957
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral tablet will be administered orally once daily.
Trial: NCT00437489
Drug: Inhaled Human Insulin (Exubera)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
Trial: NCT00437489
Drug: Inhaled Human Insulin (Exubera)
RxNorm normalized name: insulin, regular, human Inhalation Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial dose of 1mg TID of inhaled human insulin
Trial: NCT03930771
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1500mg/m2 orally per day (divided into two doses with maximum daily dose of 2500mg) on days 1 through 14.
Trial: NCT01779336
Drug: PL225B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.~* This 21 day administration will define a treatment cycle.~* Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified.
Trial: NCT01491061
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: os, two doses 12 hours apart prior to PCI
Trial: NCT02899455
Drug: HGP0904
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899455
Drug: HGP0608
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899455
Drug: HGP0816
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899455
Drug: HGP0904 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02899455
Drug: HGP0816 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03276728
Drug: Placebo PO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for oral administration
Trial: NCT03276728
Drug: Placebo IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo solution for infusion
Trial: NCT01506635
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: artificial tear twice a day
Trial: NCT04447235
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Use of the combination of ivermectin-placebo plus losartan-placebo as early treatment for COVID-19 in cancer patients
Trial: NCT01575639
Drug: Oral prednisolone
RxNorm normalized name: prednisolone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
Trial: NCT00216151
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic Acid 4mg, every three months
Trial: NCT02079909
Drug: T-817MA-H
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 224 mg or 448 mg T-817 MA once daily
Trial: NCT02079909
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03805932
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 650 mg Cycle 1, Day -2, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion; Cycles 2-8, Day 1, Day 3, Day 5. To be given 30-90 minutes prior to every moxetumomab pasudotox-tdfk infusion and recommended every 6 hours x 4 after the end of infusion. Pre-medications are given prior to rituximab/Ruxience on day 1.
Trial: NCT04498650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets to mimic PQ912 50 mg and 150 mg tablets
Trial: NCT01374321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
Trial: NCT04552041
Drug: Prospekta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT04552041
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration.
Trial: NCT03427814
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg orally twice daily
Trial: NCT03365817
Drug: Opioids taper off
RxNorm normalized name: Off! Explore
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decrease of 10% of opioid daily dose every one to two weeks until discontinuation for up to six months.
Trial: NCT03365817
Drug: Opioid stable treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No changes on prescribed opioids and adjuvant medication for the next six months
Trial: NCT00598923
Drug: phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
Trial: NCT00294671
Drug: diflunisal
RxNorm normalized name: Diflunisal
DrugBank: Diflunisal (DB00861)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: given twice daily for 24 months
Trial: NCT04020133
Drug: 0.05 mg epinephrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg epinephrine will be added to bupivacaine in both blocks to prolong their duration
Trial: NCT01955707
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matched placebo
Trial: NCT01255839
Drug: Minprostin
RxNorm normalized name: Minprostin F2 Alpha
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The prostaglandin 2 minprostin (3mg) was applied vaginally
Trial: NCT00115271
Drug: Nutritional supplements
RxNorm normalized name: nutritional supplements
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00332579
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily
Trial: NCT01618058
Drug: No Investigational Product
RxNorm normalized name: No Doz Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This study is observational in nature and no investigational product will be used.~Groups: ARV-Treated Participants, ARV-Naive Participants
Trial: NCT04120246
Drug: Alpha-tocopheryloxyacetic Acid
RxNorm normalized name: ALPHA-TOCOPHERYLOXYACETIC ACID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT03962907
Drug: BACTROBAN® Nasal ong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mupirocin, BACTROBAN® Nasal ong, 3g, GSK